ADAPTABLE: The Aspirin Study
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a patient-centered trial that will compare the effectiveness of the two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease. ADAPTABLE is considered a pragmatic trial because it is designed to reflect a “real-world” medical practice, with the actual work of the study taking place in a variety of clinical settings and among a broad patient population. The results of the trial will help answer which dosage of aspirin will reduce the risk of another heart attack or stroke based on individuals health, age, and other circumstances.
The project aims to 1) compare the effectiveness of two daily doses of aspirin (81 mg and 325 mg) in reducing a composite endpoint of all-cause death, hospitalization for nonfatal MI, or hospitalization for nonfatal stroke in high-risk patients with a history of MI or documented heart disease, 2) compare the effects of aspirin in subgroups of patients, including women vs. men, older vs. younger patients, racial minority patients vs. white patients, patients with vs. without diabetes, and patients with vs. without chronic kidney disease, and 3) develop, refine, and evaluate the infrastructure for PCORnet to conduct multiple comparative-effectiveness trials in the future.
Grantee Institution: Duke Clinical Research Institute
Mid-South PI: Sunil Kripalani, MD
Funding Source: PCORI
Participating Mid-South Sites: Vanderbilt University Medical Center, Greenway Health, Duke University, University of North Carolina at Chapel Hill, and Medical University of South Carolina